Review
doi: 10.1111/j.1749-6632.2003.tb07460.x.
PET studies on the function of dopamine in health and Parkinson's disease
Affiliations
- PMID: 12846971
- DOI: 10.1111/j.1749-6632.2003.tb07460.x
Item in Clipboard
Review
PET studies on the function of dopamine in health and Parkinson's disease
Ann N Y Acad Sci.
2003 Jun.
Abstract
Positron emission tomography (PET) can detect the presence of striatal, pallidal, midbrain, and cortical dopamine terminal dysfunction in vivo in Parkinson's disease (PD). In addition, dopamine release during motor tasks can be assessed as reflected by changes in receptor availability to PET ligands. Furthermore, the functional effects of focal dopamine replacement via implantation of fetal cells or glia-derived neurotrophic factor (GDNF) infusion into putamen can be monitored. In this review, the insight that PET has given us concerning the role of dopamine in motor control is presented, and the functional substrates underlying PD symptomatologies are discussed.
Similar articles
-
Imaging in Parkinson's disease: the role of monoamines in behavior.Biol Psychiatry. 2006 May 15;59(10):908-18. doi: 10.1016/j.biopsych.2005.12.017. Epub 2006 Apr 11. Biol Psychiatry. 2006. PMID: 16581032 Review.
-
Motor disturbance and brain functional imaging in Parkinson's disease.Eur Neurol. 1997;38 Suppl 2:26-32. doi: 10.1159/000113473. Eur Neurol. 1997. PMID: 9387800 Review.
-
Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.Neurology. 1996 May;46(5):1430-6. doi: 10.1212/wnl.46.5.1430. Neurology. 1996. PMID: 8628494
-
Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study.Brain. 2003 Feb;126(Pt 2):312-25. doi: 10.1093/brain/awg035. Brain. 2003. PMID: 12538400
-
Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease.Brain. 2009 May;132(Pt 5):1366-75. doi: 10.1093/brain/awn337. Epub 2009 Jan 19. Brain. 2009. PMID: 19153147
Cited by
-
6-[18F]fluoro-L-DOPA: a well-established neurotracer with expanding application spectrum and strongly improved radiosyntheses.Biomed Res Int. 2014;2014:674063. doi: 10.1155/2014/674063. Epub 2014 May 28. Biomed Res Int. 2014. PMID: 24987698 Free PMC article. Review.
-
The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function.Neuroimage. 2010 Apr 1;50(2):524-531. doi: 10.1016/j.neuroimage.2009.12.058. Epub 2009 Dec 23. Neuroimage. 2010. PMID: 20034580 Free PMC article.
-
Individual differences in frontal cortical thickness correlate with the d-amphetamine-induced striatal dopamine response in humans.J Neurosci. 2013 Sep 18;33(38):15285-94. doi: 10.1523/JNEUROSCI.5029-12.2013. J Neurosci. 2013. PMID: 24048857 Free PMC article. Clinical Trial.
-
Imaging in cell-based therapy for neurodegenerative diseases.Eur J Nucl Med Mol Imaging. 2005 Dec;32 Suppl 2:S417-34. doi: 10.1007/s00259-005-1909-6. Eur J Nucl Med Mol Imaging. 2005. PMID: 16267643 Review.
-
NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease.Nanomedicine. 2012 Oct;8(7):1052-69. doi: 10.1016/j.nano.2012.02.009. Epub 2012 Mar 7. Nanomedicine. 2012. PMID: 22406187 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
